Company: IMNN
Filing Date: 2025-12-31
Form Type: 424B5
Source: 0001493152-25-029712
Chunk: 7

Company: Imunon, Inc.
Filing Date: 2025-12-31
Form: 424B5
Chunk 7
---
 dividends on our common stock, and any return to investors is expected to come, if at all, only from potential increases in the price of our common stock.

At the present time, we intend to use available funds to finance our operations. Accordingly, while payment of dividends rests within the discretion of our board of directors, we have no intention of paying any cash dividends in the foreseeable future. Any return to investors on our common stock is expected to come, if at all, only from potential increases in the price of our common stock.

Purchasers may experience immediate dilution in the book value per share of the common stock purchased in the offering.

The offering price per Share in this offering is substantially higher than the net tangible book value per share of our outstanding common stock. After giving effect to the sale of shares of our common stock in the aggregate amount of approximately $7.0 million at a combined offering price per Share and Warrant of $3.61 (or $3.6099 per Pre-funded Warrant and Warrant), and after deducting commissions and estimated offering expenses, our as adjusted net tangible book value as of September 30, 2025 would have been approximately $10.4 million or approximately $2.14 per share of common stock. This represents an immediate increase in net tangible book value of approximately $0.73 per share of common stock to our existing stockholders and an immediate dilution in net tangible book value of approximately $1.47 per share of common stock to purchasers of our common stock in this offering. See “Dilution.”

You may experience future dilution as a result of future equity offerings and other issuances of our securities. In addition, this offering and future equity offerings and other issuances of our common stock or other securities may adversely affect our common stock price.

In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock. We may not be able to sell shares or other securities in any other offering at prices that equal to or greater than the price paid by any investor pursuant to this offering. In addition, investors purchasing shares or other securities in the future could have rights superior to existing stockholders. You will incur dilution upon exercise of any outstanding stock options, warrants or upon the issuance of shares of common stock under our stock incentive programs. In addition, the sale of shares in this offering and any future sales of a substantial number of shares of our common stock in the public market